SELLAS Life Sciences Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLS research report →
Range $35 – $35
Price Chart
About the company
SELLAS Life Sciences Group, Inc. , a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- CEO
- Angelos Stergiou
- IPO
- 2008
- Employees
- 13
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on SLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.78B
- P/E
- -74.79
- Fwd P/E
- 37.94
- PEG
- -1.87
- P/S
- 0.00
- P/B
- 22.82
- EV/EBITDA
- -80.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.95%
- ROIC
- -29.79%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-28,274,000
- Net Income
- $-26,863,000+13.0%
- EPS
- $-0.25+50.0%
- OCF Growth
- +19.8%
- FCF Growth
- +19.8%
- 52W High
- $24.89
- 52W Low
- $1.39
- 50D MA
- $11.16
- 200D MA
- $9.05
- Beta
- 2.70
- RSI (14)
- 56
- Avg Volume
- 9.64M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SELLAS said Q3 was a turning point, with stronger cash, debt eliminated, and clinical progress in GPS and NPS setting up key 2019 catalysts.· November 15, 2018
- Raised about $22 million in July and later received $6.6 million from JGB, leaving the company with no outstanding debt.
- GPS AML program is moving toward a registrational Phase III trial, with first patient enrollment expected in early 2019.
- Merck Keytruda basket study for GPS is active, up to 90 patients, and sites have begun screening.
- NPS/NeuVax showed positive final Phase IIb data in TNBC, including a 75.2% reduction in relapse/death risk at 24 months and p=0.013.
- Management expects to meet the FDA next month on NPS and reiterated cash runway through at least March 2019.
SELLAS reported unrestricted cash and cash equivalents of $10 million at September 30, 2018, not including the later $6.6 million JGB settlement payment. Net cash used in operating activities was $25.9 million for the nine months ended September 30, 2018, and the company said July financing brought in approximately $22 million in net proceeds. Q3 research and development expense was $1.7 million versus $1.1 million a year ago; G&A was $1.3 million versus $3.2 million; net loss attributable to common stockholders was $9.4 million, or $0.53 per share, versus a loss of $4.5 million, or $2.27 per share, in Q3 2017. Management reiterated that cash and cash equivalents are expected to fund operations at least through March 2019, with an update coming with Q4/full-year results.
Dr. Stergiou framed the quarter as a strong execution period for both clinical and corporate priorities. He emphasized that GPS has reached agreement with the FDA on a registrational Phase III AML study and that first enrollment is expected in early 2019. He also highlighted the positive NPS TNBC data, upcoming FDA discussions, and ongoing partnering efforts, while describing the JGB litigation settlement as an important balance-sheet cleanup.
Gene Mack focused on liquidity, expense trends, and runway. He said unrestricted cash was $10 million as of September 30, 2018, before the later $6.6 million JGB payment, and reiterated prior guidance that cash should fund operations through at least March 2019. He also walked through the quarter’s cost structure: R&D rose to $1.7 million from $1.1 million, G&A fell to $1.3 million from $3.2 million, and the reported Q3 loss per share was $0.53.
Analysts asked whether the additional San Antonio breast cancer data would be part of the FDA dossier, what outcomes might come from the December FDA meeting on NPS, and whether an accelerated-approval-style path is realistic in TNBC. Management said the San Antonio data would be additional, previously undisclosed Phase IIb analysis, declined to speculate on regulatory outcomes, and pointed to the DSMB’s repeated recommendation to seek FDA guidance. On GPS AML, management said one pivotal Phase III trial could be sufficient if positive and meeting the primary endpoint, and said the basket study should generate rigorous data flow in 2019.
The bullish case from the call is that SELLAS now has multiple near-term catalysts: first AML enrollment in early 2019, ongoing GPS-Keytruda screening, and an FDA meeting on NPS next month. Management also pointed to positive NPS TNBC efficacy data without new safety concerns, plus a cleaner balance sheet after the financing and JGB settlement.
The main risks are that both lead programs are still clinical-stage and hinge on regulatory discussions and future trial readouts. Management did not provide any new revenue, product, or commercialization timeline, and it reaffirmed a limited cash runway through at least March 2019. The Q&A also underscored uncertainty around the exact FDA path for NPS, which management said it would not speculate on.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 203.86M
- Float Shares
- 201.59M
of shares held by institutions
235 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 16.18M | ▲ 1.11M |
| State Street Corp | 10.37M | ▼ 2.62M |
| Vanguard Capital Management LLC | 8.94M | ▲ 716.54K |
| Vanguard Group Inc | 8.47M | ▲ 1.63M |
| Geode Capital Management, LLC | 5.17M | ▲ 287.64K |
| Susquehanna International Group, Llp | 2.64M | ▲ 587.87K |
| Vanguard Portfolio Management LLC | 2.30M | ▲ 136.48K |
| Northern Trust Corp | 1.85M | ▲ 231.14K |
| Charles Schwab Investment Management Inc | 1.80M | ▲ 1.24M |
| Morgan Stanley | 1.51M | ▲ 274.85K |
| Ubs Group AG | 1.49M | ▲ 232.52K |
| Vanguard Fiduciary Trust Co | 1.44M | ▲ 106.11K |
Held by 202 ETFs
Biggest fund positions in SLS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Burns John Thomas | sell | 3,831 |
| Nov 18, 26 | CICIC DRAGAN | sell | 6,933 |
| Nov 18, 26 | Stergiou Angelos M. | sell | 26,606 |
| Jun 16, 26 | Stergiou Angelos M. | other | 1,065,000 |
| Jan 7, 26 | Varian John | other | 50,000 |
| Jan 7, 26 | VAN NOSTRAND ROBERT L | other | 50,000 |
| Jan 7, 26 | SCHEINBERG DAVID A | other | 50,000 |
| Jan 7, 26 | CICIC DRAGAN | other | 300,000 |
| Jan 7, 26 | Burns John Thomas | other | 300,000 |
| Jan 7, 26 | Kalin Katherine Bach | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLS coverage
Recent articles, reports, and earnings notes.
No research on SLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLS report →SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
globenewswire.com · Nov 20
SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering
globenewswire.com · Nov 18
SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida Global de Pacientes com Leucemia Mieloide Aguda
globenewswire.com · Nov 17
SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda
globenewswire.com · Nov 17
SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript
seekingalpha.com · Nov 17
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
globenewswire.com · Nov 17
SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
benzinga.com · Nov 17
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
globenewswire.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.